Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).

ABSTRACT:

SUBMITTER: Byrne BJ 

PROVIDER: S-EPMC11832724 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature